Kezar Life Sciences Inc

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 1:20 pm ET in Miami, FL. A webcast from the fireside chat will be available on the “Events &.

Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update.

Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

Kezar (KZR) Falls 10% on Strategic Update, Reduces Workforce

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment is expected to extend operating capital to fund PALIZADE, Kezar's Phase 2b clinical trial in lupus nephritis. Act.

Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer

BeiGene

Bristol-Myers

Novartis

Ocular Therapeutix

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $KZR--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today announced that it entered into a collaboration and license agreement with Everest Medicines, a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, to develop and commercialize zetomipzomib, Kezar's n.

Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $KZR--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will participate in three upcoming investor conferences taking place in September: Event: 2023 Wells Fargo Healthcare Conference Location: Boston, MA Date/Time: Thursday, September 7, 2023, at 12:45 pm ET Presenter: Noreen R. Henig, M.D., Chief.

Kezar Life Sciences to Participate in Three Upcoming Investor Conferences

Allakos Inc

BioLife Solutions

Cano Health

Alaunos Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off This Month - Allakos (NASDAQ:ALLK), BioLife Solns (NASDAQ:BLFS)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $KZR--Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update.

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-Founder and Chief Executive Officer, and Noreen R. Henig, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 2:00 pm ET in New York, NY. A webcast of the fire.

Kezar Life Sciences to Participate in the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. “This quarter, Kezar continued to make meaningful progress on its clinical strategy. We remain focused on actively exploring zetomipzomib's promise in lupus nephritis an.

Kezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update. “We made tremendous progress in both of our first-in-class programs during 2022,” said John Fowler, Kezar's Co-founder and Chief Executive Officer.

Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT.

Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT.

Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Autoimmune/Complement/Inflammation panel discussion at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 am ET in Boston, MA.

Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 pm PT in San Francisco, CA.

Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Following a shift in market sentiment, I've narrowed my rating for Kezar Life Sciences from buy to hold. The market has heavily discounted KZR's growth catalysts of clinical trial updates and regulatory tailwinds.

Kezar Life Sciences: Mid-Term Growth Levers Heavily Discounted, Reduce To Hold

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib in active lupus nephritis (LN) at the American College of Rheumatology (ACR) Convergence 2022 in Philadelphia, PA.

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN's Kidney Week 2022 Annual Meeting

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology's Kidney Week 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration for zetomipzomib, its first-in-class, selective immunoproteasome inhibitor, for the treatment of autoimmune hepatitis (AIH). AIH is a rar

Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that three posters will be presented at the upcoming American College of Rheumatology (ACR) Convergence 2022, which will take place November 10 – 14, 2022 in Philadelphia, PA. Of note, the Phase 2 MISSION poster will include the full data set from the concluded

Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. “The second quarter was tremendously productive for Kezar, during which we achieved key clinical milestones, strengthened our balance sheet, and added great talent to ou

Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

News for Kezar Life Sciences Inc Stock (KZR)